ASCO 2024 oral presentation of darovasertib neoadjuvant UM Phase 2 investigator-sponsored trial on June 3rd, and targeting neoadjuvant UM update in over 30.
Targeting two independent Phase 2 clinical efficacy updates for darovasertib in neoadjuvant uveal melanoma in mid-2024, including from the Phase 2 IST and Phase 2 company-sponsored studyTargeting.
IDEAYA Biosciences (IDYA) Announces First-Patient-In for Company-Sponsored Phase 2 Trial of Darovasertib streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Dosed a first patient in a company-sponsored global Phase 2 clinical trial evaluating darovasertib as neoadjuvant and adjuvant therapy in primary uveal.